

**AMENDMENT FOR DISTRIBUTION 20.0--SCHIZOPHRENIA
NIMH HUMAN GENETICS INITIATIVE DISTRIBUTION AGREEMENT**

NOW, THEREFORE, it is mutually agreed that the National Institute of Mental Health (NIMH) Human Genetics Initiative Distribution Agreement signed by NIMH, the center for Genetic Studies, and _____ **(PLEASE PRINT)** as the Receiving Institution is amended to include the following text in paragraph 14 under the section, Acknowledgement for Schizophrenia Biomaterials and Clinical Data:

Biomaterials and phenotypic data were obtained from the following projects that participated in the NIMH Schizophrenia Genetics Initiative:

SZ Dataset 30 used biomaterials from the NIMH Schizophrenia Genetics Initiative Release 1.0 and Release 3.0, the NIMH Genetics Initiative Control Database Release 3.0, and the Environmental Catchment Area ADHD Study. The study was funded by the Pfizer Fellowship in Biological Psychiatry, a NARSAD/Sidney R. Baer Jr. Foundation Young Investigator Award, the Institute of Mental Health Research, the State of Arizona Department of Health Services and Biomedical Research Collaborative, and NIMH grants R01MH097803, R01MH083823, R01MH067921. Principal Investigators were Amelia Gallitano, M.D., Ph.D. (University of Arizona College of Medicine, Phoenix, AZ), Matthew Huentelman, Ph.D. (Translational Genomics Research Institute, Phoenix, AZ), and Richard Todd, M.D., Ph.D. (Washington University School of Medicine, St. Louis, MO).

SZ Dataset 29 (Sweden Study) -- The collection of data and biomaterials for this study was supported by funding provided by the NIMH (R01 MH077139 to Patrick F. Sullivan and R01 MH095034 to Pamela Sklar), the Stanley Center for Psychiatric Research, the Sylvan Herman Foundation, the Friedman Brain Institute at the Mount Sinai School of Medicine, the Karolinska Institutet, Karolinska University Hospital, the Swedish Research Council, the Swedish County Council, the Söderström Königska Foundation, and the Netherlands Scientific Organization (NWO 645-000-003). Co-principal investigators involved in this study were Pamela Sklar (Mount Sinai School of Medicine), Christina M. Hultman (Karolinska Institutet, Stockholm, Sweden), and Patrick F. Sullivan (University of North Carolina and Karolinska Institutet, Stockholm, Sweden). We are deeply grateful for the participation of all subjects contributing to this research and to the collection team that worked to recruit them.

NIMH Study SZ 0 -- Data and biomaterials were collected in three projects that participated in the National Institute of Mental Health (NIMH) Schizophrenia Genetics Initiative. From 1991-97, the Principal Investigators and Co-Investigators were: Harvard University, Boston, MA, U01 MH46318, Ming T. Tsuang, M.D., Ph.D., D.Sc., Stephen Faraone, Ph.D., and John Pepple, Ph.D.; Washington University, St. Louis, MO, U01 MH46276, C. Robert Cloninger, M.D., Theodore Reich, M.D., and Dragan Svrakic, M.D.; Columbia University, New York, NY U01 MH46289, Charles Kaufmann, M.D., Dolores Malaspina, M.D., and Jill Harkavy Friedman, Ph.D.

NIMH Study 3 -- The data from the Han Chinese Schizophrenia Linkage Study were collected with funding from grant R01 MH59624 from the US National Institute of Mental Health to Ming T. Tsuang, M.D., Ph.D. (Principal Investigator). Other participants in the US were Stephen V. Faraone, Ph.D. (Co-Principal Investigator), Shao Zhu, M.D. (Project Coordinator) and Xingjia Cui, M.D. (Project Coordinator).

The project leaders in Taiwan were Hai-Gwo Hwu, M.D. (Taiwan Principal Investigator, National Taiwan University Hospital), Wei J. Chen, M.D. Sci.D. (Taiwan Co- Principal Investigator). Other participants in Taiwan were: Chih-Min Liu, M.D., Shih-Kai Liu, M.D., Ming-Hsien Shieh, M.D., Tzung-Jeng Hwang, M.D., M.P.H., Ming-Ming Tsuang, M.D., Wen Chen OuYang, M.D., Ph.D.,

**AMENDMENT FOR DISTRIBUTION 20.0--SCHIZOPHRENIA
NIMH HUMAN GENETICS INITIATIVE DISTRIBUTION AGREEMENT**

Chun-Ying Chen, M.D., Chwen-Cheng Chen, M.D., Ph.D., Jin-Jia Lin, M.D., Frank Huang-Chih Chou, M.D., Ph.D., Ching-Mo Chueh, M.D., Wei-Ming Liu, M.D., Chiao-Chicy Chen, M.D., Jia-Jiu Lo, M.D., Jia-Fu Lee, M.D., Ph.D. Seng Shen, M.D., Yung Feng, M.D., Shin-Pin Lin, M.D., Shi-Chin Guo, M.D., Ming-Cheng Kuo, M.D., Liang-Jen Chuo, M.D., Chih-Pin Lu, M.D., Deng-Yi Chen, M.D., Huan-Kwang Ferng, M.D., Nan-Ying Chiu, M.D., Wen-Kun Chen, M.D., Tien-Cheng Lee, M.D., Hsin-Pei Tang, M.D., Yih-Dar Lee, M.D., Wu-Shih Wang, M.D., For-Wey Long, M.D., Ph.D., Tiao-Lai Huang, M.D., Jung-Kwang Wen, M.D., Cheng-Sheng Chen, M.D., Wen-Hsiang Huang, M.D., Shu-Yu Yang, M.D., Mei-Hua Hall, Cheng-Hsing Chen, M.D.

The project leaders in the People's Republic of China were Xiaogang Chen, M.D., Ph.D. (China Principal Investigator, Institute of Mental Health, Xiang-ya Teaching Hospital, Central South University), and Xingqun Ni, M.D. (Original Principal Investigator, Sun Yat-sen University). Other participants in China were: Liwen Tan, M.D., Ph.D, Liang Zhou, M.D., Ph.D, Jiajun Shi, M.D., Ph.D, Xiaoling He, M.D., Ph.D, Xiogzhao Zhu, M.D., Ph.D, Lingjian Li, M.D., Ph.D, Ming Wang, M.D., Tiansheng Guo, M.D., Xiaqi Shen, M.D., Ph.D., Jinghua Yang, M.D.

NIMH Study 6 -- Data and biomaterials generated in Study 6 were collected by the Molecular Genetics of Schizophrenia, part 1 (MGS1), and funded by collaborative NIMH grants to Evanston Northwestern Healthcare/Northwestern University, Evanston, IL, MH059571, Pablo V. Gejman, M.D. (Collaboration Coordinator; PI), Alan R. Sanders, M.D.; Emory University School of Medicine, Atlanta, GA, MH59587, Farooq Amin, M.D. (PI); University of California, San Francisco, CA, MH60870, William Byerley, M.D. (PI); University of Iowa, Iowa, IA, MH59566, Raymond Crowe, M.D. (PI), Donald Black, M.D.; Washington University, St. Louis, MO, U01, MH060879, C. Robert Cloninger, M.D. (PI); University of Colorado, Denver, CO, MH059565, Robert Freedman, M.D. (PI), Ann Olincy, M.D.; University of Pennsylvania, Philadelphia, PA, MH061675, Douglas Levinson, M.D. (PI), Nancy Buccola, APRN, B.C., M.S.N., New Orleans, Louisiana; University of Queensland, Queensland, Australia, MH059588, Bryan Mowry, M.D. (PI); Mt. Sinai School of Medicine, New York, NY, MH059586, Jeremy Silverman, Ph.D. (PI).

NIMH Study 9 -- Data and biomaterials for the CBDB/NIMH Sibling Study were collected while the responsible investigators were in the Clinical Brain Disorders Branch (Weinberger Lab) of the Intramural Research Program (IRP) of the National Institute of Mental Health (NIMH), which funded the project. The Principal Investigator was Daniel R. Weinberger, M.D., and Co-Investigators were Michael F. Egan, M.D., and Richard E. Straub, Ph.D.

NIMH Study 12 -- Portuguese island families were contributed by Dr. Carlos Pato at the University of Southern California and his staff. This work was sponsored by NIMH grants MH52618 and MH058693.

NIMH Study 13 -- Data and biomaterials used in this research report were collected by the International Neuro-Genetics Association of Spanish America and the United States (INGASU), and funded by a collaborative NIMH grant (Genetics of Schizophrenia in Latino Populations) to Dr. Michael Escamilla (University of Texas Health Science Center at San Antonio) (MH60881) and to Dr. Ricardo Mendoza (University of California at Los Angeles-Harbor)(MH60875). Additional principal investigators who participated in these grants were Dr. Henriette Raventos (University of Costa Rica, San Jose, Costa Rica), Dr. Alfonso Ontiveros (Instituto de Informacion de Investigacion en Salud Mental, Monterrey, Mexico), Dr. Humberto Nicolini (Medical and Family Research Group, Carracci S.C., Mexico City, Mexico), Dr. Rodrigo Munoz (Family Health Centers of San Diego, California), and Dr. Alvaro Jerez (Centro Internacional de Trastornos Afectivos y de la Conducta Adictiva-CITACA, Guatemala). Additional investigators from the University of Texas Health Science Center at San Antonio included Dr. Albana Dassori

**AMENDMENT FOR DISTRIBUTION 20.0--SCHIZOPHRENIA
NIMH HUMAN GENETICS INITIATIVE DISTRIBUTION AGREEMENT**

and Dr. Rolando Medina.

NIMH Study 15 -- The principal investigators of the Neurobehavioral Family Study of Schizophrenia project were Raquel Gur, M.D., Ph.D., Vishwajit Nimgaonkar, Ph.D., and Laura Almasy, Ph.D. This study was supported by grants MH042191, MH063480, and MH061622.

NIMH Study 17 -- The principal investigators of the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) trial were Jeffrey A. Lieberman, M.D., T. Scott Stroup, M.D., M.P.H., and Joseph P. McEvoy, M.D. The CATIE trial was funded by a grant from the National Institute of Mental Health (N01 MH900001) along with MH074027 (PI PF Sullivan). Genotyping was funded by Eli Lilly and Company.

NIMH Study 22 -- Study 22 was funded by a collaborative NIMH grant, Project Among African Americans to Explore Risks for Schizophrenia (PAARTNERS). The principal investigators for the PAARTNERS study were supported by funding from the National Institute for Mental Health grant RO1 MH66006 (L. Dianne Bradford, Morehouse School of Medicine), R01 MH66278 (Bernie Devlin, University of Pittsburgh), R01 MH-066049 (Neil Edwards, University of Tennessee at Memphis), R01MH66181-03 (Rodney Go, University of Alabama at Birmingham), R01 MH66121 (Raquel Gur, University of Pennsylvania), R01 MH066005 (Joseph Kwentus, University of Mississippi), R01 MH66050 (Joseph McEvoy, Duke University), R01 MH66263 (Vishwajit Nimgaonkar) and RO 1MH66004 (Alberto Santos, Medical University of South Carolina). Additional investigators who contributed to this study were Robert M. Savage (University of Alabama at Birmingham), Judith O'Jile (University of Mississippi), Trina Allen (Duke University), Monica E. Calkins and Ruben C. Gur (University of Pennsylvania), Muktar H. Aliyu, M.D., Dr.P.H. (Mayo Clinic, College of Medicine, Rochester, MN), and Paul D. Lyons, M.D., Ph.D. (University of Virginia, Department of Neurology, Charlottesville, VA).

NIMH Study 23 -- Data and biomaterials used in Study 23 were collected by the University of Pittsburgh and funded by an NIMH grant (Genetic Susceptibility in Schizophrenia, MH56242) to Dr. Vishwajit Nimgaonkar, M.D., Ph.D. Additional Principal Investigators on this grant include Dr. Smita Deshpande, M.D., Dr. Ram Moanohar, Lohia Hospital, New Delhi, India; and Dr. Michael Owen, M.D., Ph.D., University of Wales College of Medicine, Cardiff, UK.

NIMH Study 27 (COGS-1) -- Data and biomaterials were collected by the NIMH Consortium on the Genetics of Schizophrenia between 9/2003 - 8/2008 ("COGS-1"). The Principal Investigators and Co-Investigators during this period were: David L. Braff, M.D., Kristin S. Cadenhead, M.D., Monica E. Calkins, Ph.D., Dorcas J. Dobie, M.D., Robert Freedman, M.D., Michael F. Green, Ph.D., Tiffany A. Greenwood, Ph.D., Raquel E. Gur, M.D., Ph.D., Ruben C. Gur, Ph.D., Gregory A. Light, Ph.D., Keith H. Nuechterlein, Ph.D., Ann Olincy, M.D., Allen D. Randant, M.D., Nicholas J. Schork, Ph.D., Larry J. Seidman, Ph.D., Larry J. Siever, M.D., Jeremy M. Silverman, Ph.D., William S. Stone, Ph.D., Catherine A. Sugar, Ph.D., Neal R. Swerdlow, M.D., Ph.D., Debby W. Tsuang, M.D., Ming T. Tsuang, M.D., Ph.D., D.Sc., and Bruce I. Turetsky, M.D. COGS-1 inquiries should be directed to the attention of David Braff, M.D. at dbraff@ucsd.edu. Funding sources: COGS-1 was supported by grants R01MH065571, R01MH065578, R01MH065558, R01MH065588, R01MH065707, R01MH065562, and R01MH065554 from the National Institute of Mental Health. Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to the Johns Hopkins University, Contract number HHSN268200782096C.

NIMH Study 29 -- Data and biomaterials generated in Study 29 were collected by the Molecular

**AMENDMENT FOR DISTRIBUTION 20.0--SCHIZOPHRENIA
NIMH HUMAN GENETICS INITIATIVE DISTRIBUTION AGREEMENT**

Genetics of Schizophrenia, part 2 (MGS2), and funded by collaborative NIMH grants to Evanston Northwestern Healthcare/Northwestern University, Evanston, IL, MH59571, Pablo V. Gejman, M.D. (Collaboration Coordinator; PI), Alan R. Sanders, M.D.; Stanford University, Palo Alto, CA, MH61675, Douglas F. Levinson M.D. (PI); Louisiana State University, New Orleans, LA, MH67257, Nancy G. Buccola APRN, B.C., M.S.N. (PI); University of Queensland, Brisbane, Queensland, Australia, MH59588, Bryan J. Mowry, M.D. (PI); University of Colorado, Denver, CO, MH59565, Robert Freedman, M.D. (PI), Ann Olincy, M.D.; Emory University School of Medicine, Atlanta, GA, MH59587, Farooq Amin, M.D. (PI); University of Iowa, Iowa, IA, MH59566, Donald W. Black, M.D. (PI), Raymond R. Crowe, M.D.; Mount Sinai School of Medicine, New York, NY, MH59586, Jeremy M. Silverman, Ph.D. (PI); University of California, San Francisco, CA, MH60870, William F. Byerley, M.D. (PI); Washington University, St. Louis, MO, MH60879, C. Robert Cloninger, M.D. (PI).

NIMH Study 42 -- Data and biomaterials used in Study 42 were collected by The Johns Hopkins University and funded by an NIMH grant (A Genome-wide SNP Association Study: Schizophrenia, MH068406) to Dr. Ann Pulver, Sc.D. Co-investigators at Johns Hopkins University included Dr. Gerald Nestadt, M.D., Dr. Kung Yee Liang, Ph.D., Dr. M. Daniele Fallin, Ph.D., Dr. Dimitrios Avramopoulos, M.D., Ph.D., and Dr. David Valle, M.D. Co-investigators also included Dr. Jeremy Silverman, Ph.D. (Mount Sinai School of Medicine, New York, NY).

NIMH Study 59 -- Data and biomaterials used in Study 59 (Site 100) were collected with funding from grant R01MH07875 from the US National Institute of Mental Health to Dr. Roel Ophoff (Principal Investigator) at University of California Los Angeles (UCLA). Other UCLA contributors are Drs. Nelson Freimer and Rita Cantor. Clinical collaborators include the members of Genetic Risk Outcome of Psychosis (GROUP) consortium from The Netherlands: René S. Kahn, M.D., Ph.D. (University Medical Center Utrecht, The Netherlands); Don H. Linszen, M.D., Ph.D. (University of Amsterdam, The Netherlands); Jim Van Os, M.D., Ph.D. (Maastricht University Medical Centre, The Netherlands); Durk Wiersma, M.D., Ph.D. (University Medical Center Groningen, The Netherlands); Richard Bruggeman, M.D., Ph.D. (University Medical Center Groningen, The Netherlands); Wiepke Cahn, M.D., Ph.D. (University Medical Center Utrecht, The Netherlands); Lieuwe De Haan, M.D., Ph.D. (University of Amsterdam, The Netherlands); Lydia Krabbendam, Ph.D. (Maastricht University Medical Centre, The Netherlands). All laboratory coordinating efforts were performed by Eric Strengman (University Medical Center Utrecht, The Netherlands).

NIMH Study 67 -- The collection of pedigree samples and diagnostic information was supported by National Institute of Health Grant R01MH061884 (Population Based Mapping of Schizophrenia Genes; PI: Michael Escamilla). This work was done collaboratively with the following institutions: University of Texas Health Science Center at San Antonio, Texas Tech University Health Sciences Center El Paso, and the University of Costa Rica. Investigators contributing to this work included: Michael Escamilla, M.D., Juan Zavala, M.D., Mercedes Ramirez, M.D. (Texas Tech University Health Sciences Center El Paso), Albana Dassori, M.D. and Robin Leach, Ph.D. (University of Texas Health Science Center at San Antonio), Henriette Raventos, M.D., Javier Contreras Rojas, M.D., Patricia Montero, M.D., and Rodolfo Salazar, M.D. (University of Costa Rica).

NIMH Study 68 -- Data and biomaterials were collected as part of a study examining people who did or did not abuse cannabis when they were adolescents and who either had developed schizophrenia or did not. Family history for psychiatric disorders, particularly the psychoses, was obtained on each individual and familial risk for schizophrenia was quantified. This project was supported by a grant (R01DA021576) to Lynn E. DeLisi, MD, formally at New York

**AMENDMENT FOR DISTRIBUTION 20.0--SCHIZOPHRENIA
NIMH HUMAN GENETICS INITIATIVE DISTRIBUTION AGREEMENT**

University Langone School of Medicine and then at Harvard Medical School. Veronica Tomaselli was the research coordinator for this project at New York University, while Ashley Proal was the research coordinator at Harvard Medical School. The investigators are grateful to the several hundred participants and their families who contributed data for this project.

NIMH Study 72 (PROACTIVE) -- Data used were obtained from the limited access datasets distributed from the NIH-supported *"Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy"* (PROACTIVE). This is a multisite, clinical trial of persons with Schizophrenia comparing the effectiveness of randomly assigned medication treatment. The study was supported by NIMH Grant #s U01MH070007-01, U01MH070023, U01MH070011, U01MH070009, U01MH070008, U01MH070017, U01MH070010, U01MH070016, U01MH070012. The ClinicalTrials.gov identifier is NCT00330863.

NIMH Study 76 -- Data and biomaterials were collected as part of a genetics study of schizophrenia supported by National Institutes of Health grant R01MH085548. This study is based at the University of Southern California. The Principal Investigator is Carlos N. Pato, M.D., Ph.D. and Michele T. Pato, M.D.; Co-investigators are Helena Medeiros, MSW, LICSW; James A. Knowles, M.D., Ph.D., Janet L. Sobell, Ph.D.; Stephen Marder, M.D.; Diana Perkins, M.D., MPH; Peter Buckley, M.D.; Christopher Morley, Ph.D.; Dolores Malaspina, M.D.; Evelyn Bromet, Ph.D., Laura Fochtmann, M.D.; Douglas Lehrer, M.D.; Fabio Macciardi, M.D., Ph.D., Marquis Vawter, Ph.D.; Humberto Nicolini, M.D., Ph.D.; Mark Rapaport, M.D.; Jeffrey Rafovsky, M.D., Maria Azevedo, M.D.; Ayman Fanous, M.D.; and Michael Escamilla, M.D. All are members of the Genomic Psychiatry Cohort Consortium (GPCC). Other GPCC members are Brooke Sklar, Colony Abbott, Rute Ferreira, Becky L. Kinkead, and Nuria Lanzagorta. The investigators wish to acknowledge the tremendous efforts of all who contributed to the ascertainment of study subjects and biomaterials (clinical interviewers, phlebotomists, Rutgers University Cell and DNA Repository). We are especially grateful to all study participants.

NIMH Study 82 – The collection of data and biomaterials comes from two collaborative studies funded by the NIMH: 1/2-Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan (5R01MH085560; PI: Ming T. Tsuang, M.D., Ph.D.) and 2/2-Expanding Rapid Ascertainment Networks of Schizophrenia Families in Taiwan (5R01MH085521; PI: Stephen J. Glatt, Ph.D.).

We acknowledge the following researchers and clinicians performing the recruitment of the study sample in Taiwan: Hai-Gwo Hwu, M.D., Wei J. Chen, M.D., Sc.D., Ling-Ling Yeh, Ph.D., Chih-Min Liu, M.D., Ph.D., Tzung-Jeng Hwang, M.D., Ph.D., Ming H. Hsieh, M.D., Ph.D., Chen-Chung Liu, M.D., Ph.D., Yi-Ling Chien, M.D., Yi-Ting Lin, M.D., Wen-Chen Ou-Yang, M.D., Ph.D.

We also acknowledge all the participating psychiatric service settings for sample recruitment in Taiwan, including 116 psychiatric hospitals, 9 psychiatric primary care clinics, and 40 community rehabilitation units.

NIMH Study 85 -- Data and biomaterials were collected as part of a study examining people who were at familial high-risk for schizophrenia based on having at least 2 relatives with illness within the family (at least one being a first-degree relative compared with controls who were at low familial risk for schizophrenia). Structural and functional MRI examining language processing were obtained on each participant and samples for DNA were stored in the NIMH repository. This project was supported by a grant (R21MH083205) to Lynn E. DeLisi at the Department of Psychiatry at Harvard Medical School. Scans were performed at Massachusetts Institute of

AMENDMENT FOR DISTRIBUTION 20.0--SCHIZOPHRENIA NIMH HUMAN GENETICS INITIATIVE DISTRIBUTION AGREEMENT

Technology under the direction of Dr. Susan Gabrieli. These individuals were recruited from throughout the Boston and New England region. They received cognitive testing at The Beth Israel-Deaconess Medical Center. Drs Larry Seidman, Matcheri Keshevan, Theo Manschreck, Martha Shenton and Marek Kubicki were collaborators. Dr. Heidi Thermenos performed the MRI scans and developed the fMRI protocol with Drs. Gina Kuperberg and Susan Gabrieli. Gul Jabbar was the research coordinator. The investigators are grateful to the many families who took time to participate in this study.

NIMH Study 90 -- Drs. Brien P. Riley, Aiden Corvin, Kenneth S. Kendler, and Michael Gill sincerely thank all patients who contributed to this study and all staff who facilitated their involvement. Funding for this study (A genomewide association study of schizophrenia in Ireland) was provided by the Wellcome Trust Case Control Consortium 2 project (085475/B/08/Z and 085475/Z/08/Z), the Wellcome Trust (072894/Z/03/Z, 090532/Z/09/Z and 075491/Z/04/B), The US National Institute of Mental Health (MH041953 and MH083094) and Science Foundation Ireland (08/IN.1/B1916). P. Donnelly was supported in part by a Wolfson-Royal Society Merit Award. We also thank S. Bertrand, J. Bryant, S.L. Clark, J.S. Conquer, T. Dibling, J.C. Eldred, S. Gamble, C. Hind, A. Wilk, C.R. Stribling and S. Taylor of the Wellcome Trust Sanger Institute's Sample and Genotyping Facilities for technical assistance. We thank S. Leslie for support with the HLA imputation analysis. We acknowledge use of the Irish GeneBank sample, the British 1958 Birth Cohort DNA collection funded by the Medical Research Council (grant G0000934) and the Wellcome Trust (grant 068545/Z/02) and of the UK National Blood Service controls funded by the Wellcome Trust.

NIMH Study 91 -- Study 91 was funded by NIMH grant 3RC2MH089915-01W1 and 3RC2MH089915-02S1. The Principal Investigators were David Goldstein, Joseph McEvoy, and Anna Need (Duke University).

NIMH Study 92 -- Data and biomaterials in Study 92 were collected as part of a longitudinal study of epigenetics of schizophrenia, supported by National Institutes of Mental Health grants RC2MH089859 and RC2 MH089973 to Vishwajit L Nimgaonkar, M.D., Ph.D., University of Pittsburgh, and Raquel Gur, M.D., Ph.D., University of Pennsylvania, respectively. This project was part of a network of three NIMH-supported Consortia: The 8-site Consortium on the Genetics of Schizophrenia (COGS); the 3-site Multiplex-Multigenerational Investigation (MGI); and the 8-site Project among African-Americans to Explore Risks for Schizophrenia (PAARTNERS). The consortium was complemented by investigators from Johns Hopkins University (PI: A. Feinberg, M.D., Ph.D.), Rutgers University (D. Fugman, Ph.D.) and the Southwest Foundation for Biomedical Research (PI: L. Almasy, Ph.D.). The study coordinators were Sue Clifton (University of Pittsburgh) and Amy Cassidy (University of Pennsylvania). The data managers were Joel Wood (University of Pittsburgh) and Kosha Ruparel (University of Pennsylvania).

NIMH Study 94 -- The collection of data and biomaterials for this study was supported by funding provided by R01 MH080403 (Patrick F. Sullivan, Edwin JCG van den Oord) from the US National Institute of Mental Health via the American Recovery and Reinvestment Act of 2009. Drs. Denis Fourches and Alexander Tropsha acknowledge the support from National Science Foundation grant ABI 10-567. The study was led by Patrick F. Sullivan, L. Fredrik Jarskog, Jeffrey A. Lieberman, James L. Kennedy, and Mark J. Daly. Drs. Thomas Lehner (NIMH) and David Goldstein (Duke University) were also involved in assisting with this project. We acknowledge the assistance of Dr. Michael Karukin (Teva Pharmaceuticals) and Drs. Rafael Muniz and Vinod Kumar (Novartis) for help in accessing US national clozapine registries. Drs. Stanton Gerson (Department of Hematology, Case Western Reserve), Armond Goldman

**AMENDMENT FOR DISTRIBUTION 20.0--SCHIZOPHRENIA
NIMH HUMAN GENETICS INITIATIVE DISTRIBUTION AGREEMENT**

(Department of Immunology, University of Texas Galveston), and Nancy Berliner (Department of Hematology, Harvard University) provided input on mechanisms of agranulocytosis.

NIMH Study 104 (ACLAIMS) -- Data used were obtained from the limited access datasets distributed from the NIH-supported "*A Comparison of Long-Acting Injectable Medications for Schizophrenia*" (ACLAIMS). This is a multisite, clinical trial of persons with schizophrenia comparing the risk and benefits of two FDA-approved long-acting injectable medications (paliperidone palmitate and haloperidol decanoate). The study was supported by NIMH Contract # R01MH081107 to the New York State Psychiatric Institute. The ClinicalTrials.gov identifier is NCT01136772.

NIMH Study 122 – This work was supported by the National Institute of Mental Health. This organization is dedicated to research focused on the understanding, treatment to help answer important scientific questions about mental illness. Research is under the title of *Characterization of a Mendelian Form of Psychosis in a Population Isolate*. Conducted by Project Investigators: Henriette Raventós, David Glahn, and Laura Almasy. Grant number R56MH097940. We thank our colleagues from Molecular and Cell Biology Research Institute who collected the data as well as the family at the central valley for such a significant cooperation. Most importantly, we thank the families who have participated in and contributed to these studies.

**AMENDMENT FOR DISTRIBUTION 20.0--SCHIZOPHRENIA
NIMH HUMAN GENETICS INITIATIVE DISTRIBUTION AGREEMENT**

DATED SIGNATURES

Principal Investigator, **PLEASE PRINT**

Signature and **Date**, Principal Investigator

Signature and **Date**, Receiving Institution's Authorized Representative

Signature and **Date**, NIMH Repository & Genomics Resource's Authorized Representative,
Rutgers University

Signature and **Date**, NIMH's Authorized Representative